Ticagrelor or Prasugrel for Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention

医学 普拉格雷 替卡格雷 急性冠脉综合征 经皮冠状动脉介入治疗 传统PCI 内科学 心脏病学 危险系数 心肌梗塞 临床终点 随机对照试验 置信区间
作者
J J Coughlan,Alp Aytekin,Shqipdona Lahu,Gjin Ndrepepa,Maurizio Menichelli,Katharina Mayer,Jochen Wöhrle,Isabell Bernlochner,Senta Gewalt,Bernhard Witzenbichler,Willibald Hochholzer,Dirk Sibbing,Salvatore Cassese,Dominick J. Angiolillo,Rayyan Hemetsberger,Christian Valina,Arne Müller,Sebastian Kufner,Christoph Liebetrau,Erion Xhepa
出处
期刊:JAMA Cardiology [American Medical Association]
卷期号:6 (10): 1121-1121 被引量:23
标识
DOI:10.1001/jamacardio.2021.2228
摘要

Importance: It is unclear whether ticagrelor or prasugrel hydrochloride is superior for patients with acute coronary syndrome (ACS) treated with percutaneous coronary intervention (PCI). Objective: To assess the safety and efficacy of ticagrelor vs prasugrel for patients with ACS treated with PCI. Design, Setting, and Participants: A prespecified analysis was performed of a postrandomization subgroup of 3377 patients who presented with ACS and were treated with PCI in the investigator-initiated, multicenter, phase 4, open-label Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 5 randomized clinical trial, conducted from September 1, 2013, to February 28, 2018. Statistical analysis was performed from September 1, 2020, to January 30, 2021. Analysis was performed according to the intention-to-treat principle. Interventions: Patients were randomly assigned to a ticagrelor-based or prasugrel-based strategy. This analysis focuses on the subgroup of patients who underwent PCI that was formed after randomization. Main Outcomes and Measures: The primary end point was a composite consisting of all-cause death, myocardial infarction, or stroke at 12 months. The safety end point was Bleeding Academic Research Consortium (BARC) type 3 to 5 bleeding. Results: The ticagrelor group comprised 1676 patients (1323 men [78.9%]; mean [SD] age, 64.4 [12.0] years), and the prasugrel group comprised 1701 patients (1341 men [78.8%]; mean [SD] age, 64.7 [12.0] years). The primary end point occurred for 162 patients (9.8%) in the ticagrelor group and 120 patients (7.1%) in the prasugrel group (hazard ratio [HR], 1.41; 95% CI, 1.11-1.78; P = .005). Myocardial infarction occurred in 88 patients (5.3%) in the ticagrelor group compared with 55 patients (3.8%) in the prasugrel group (HR, 1.67; 95% CI, 1.19-2.34; P = .003). The safety end point, BARC type 3 to 5 bleeding, occurred in 84 of 1672 patients (5.3%) in the ticagrelor group and 78 of 1680 patients (4.9%) in the prasugrel group (HR; 1.10; 95% CI, 0.81-1.50; P = .54). Conclusions and Relevance: Among patients presenting with ACS who were treated with PCI, the incidence of the primary composite end point occurred less frequently for patients who received prasugrel compared with those who received ticagrelor. The incidence of bleeding events was comparable between the 2 groups. These results suggest that, for patients presenting with ACS who undergo PCI, a prasugrel-based strategy is superior to a ticagrelor-based strategy. However, because these observations are based on a postrandomization subgroup, these findings should be regarded as hypothesis generating and dedicated randomized clinical trials may be warranted to confirm these findings. Trial Registration: ClinicalTrials.gov Identifier: NCT01944800.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
臣四水儿完成签到 ,获得积分10
刚刚
英俊的铭的应助被Cx330采纳,获得10
刚刚
感谢sisisi转发科研通微信,获得积分50
1秒前
自由甜瓜完成签到,获得积分10
1秒前
任性的傲柏完成签到,获得积分0
1秒前
Eli发布了新的文献求助10
1秒前
00gi完成签到,获得积分10
1秒前
小冯1完成签到,获得积分10
2秒前
郑瑞完成签到 ,获得积分10
2秒前
清新的石头完成签到,获得积分10
2秒前
好好完成签到,获得积分10
2秒前
yygz0703完成签到 ,获得积分10
2秒前
梨恩完成签到,获得积分20
2秒前
丁丁当当完成签到,获得积分10
2秒前
hitech完成签到,获得积分10
3秒前
感谢selena转发科研通微信,获得积分50
3秒前
777完成签到 ,获得积分10
3秒前
阿拉丁发布了新的文献求助20
3秒前
谦让的鹏煊完成签到,获得积分10
4秒前
风随完成签到,获得积分10
4秒前
婉莹完成签到 ,获得积分0
4秒前
林慕然2023完成签到,获得积分10
4秒前
唠叨的访文完成签到,获得积分10
5秒前
hongtaoli2024完成签到 ,获得积分10
5秒前
感谢kinlo97转发科研通微信,获得积分50
5秒前
完美世界的应助被梨恩采纳,获得10
6秒前
只道寻常完成签到,获得积分10
7秒前
Lily完成签到,获得积分10
7秒前
封典完成签到,获得积分10
7秒前
感谢负责的代亦转发科研通微信,获得积分50
8秒前
zh完成签到 ,获得积分10
8秒前
8秒前
valiente完成签到,获得积分10
8秒前
wenli完成签到,获得积分10
8秒前
Bryant完成签到,获得积分10
9秒前
三脸茫然完成签到 ,获得积分0
9秒前
xxx完成签到 ,获得积分10
9秒前
StarXG完成签到,获得积分10
9秒前
10秒前
wqwq69完成签到,获得积分10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173463
求助须知:如何正确求助?哪些是违规求助? 9565690
关于积分的说明 21781315
捐赠科研通 7767647
什么是DOI,文献DOI怎么找? 3431597
关于科研通互助平台的介绍 2555855
邀请新用户注册赠送积分活动 2476808